^
    Back
    Association details:
    Biomarker:RB1 mutation
    Cancer:Meningioma
    Drug:Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Clin Transl Oncol
    Title:

    Evaluating anti-tumor activity of palbociclib plus radiation in anaplastic and radiation-induced meningiomas: pre-clinical investigations

    Published date:
    11/22/2020
    Excerpt:
    …Palbociclib plus radiation treatment reduced proliferation and has additional effects on cell cycling, including induction of an RB-associated G (1) arrest in Rb+ AM…
    DOI:
    10.1007/s12094-020-02341-7